Patient Preferences in Treatment of Haemophilia A With and Without Inhibitors: a Discrete Choice Experiment in Germany

This study aims to generate structured patient preference evidence on prophylactic treatment options for haemophilia A for adults with and without inhibitors to support health technology assessment and benefit evaluation processes. The study will examine how individuals with haemophilia A evaluate trade-offs between treatment effectiveness, safety, and treatment administration characteristics when choosing between prophylactic therapies. Participants will repeatedly choose between hypothetical treatment profiles that differ in clinically relevant attributes and levels.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Haemophilia A Blood Coagulation Disorders Blood Coagulation Disorders, Inherited Coagulation Protein Disorders Congenital, Hereditary, and Neonatal Diseases and Abnormalities Genetic Diseases, Inborn Hematologic Diseases Hemic and Lymphatic Diseases Hemophilia A Hemorrhagic Disorders

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Novo Nordisk Investigational Site

Mainz, Gonsenheim, 55124, Germany

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Informed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol).
Participant has the mental capacity and sufficient German language proficiency to understand the study procedures and to complete the survey.
Age above or equal to 18 years at the time of signing informed consent.
Validated diagnose with haemophilia A, with and without inhibitors.
Resident in Germany.

Exclusion criteria

No provision of informed consent in this study.
Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation
Age below 18 years at the time of signing informed consent.
Absence of a diagnosis of haemophilia A.
No residence in Germany.

Treatment and study plan

No treatment given

Other

Web-based survey

Primary outcomes

Choice of treatment alternative in discrete choice tasks

Time frame: Day 1

Categorical

Study contacts

Contact information is provided by the study sponsor or research team.

Novo Nordisk

CONTACT

[email protected]

(+1) 866-867-7178

Sponsors and collaborators

Lead sponsor

Novo Nordisk A/S

Industry

Registry information

Important dates

Study start: 2026
Primary completion: 2026
Study completion: 2026
First posted: Jun 17, 2026
Registry last updated: Jun 17, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Recruiting